US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Biovaxys Technology Corp
(CSE:
BIOV
)
0.0700
UNCHANGED
Last Price
Updated: 3:55 PM EDT, May 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biovaxys Technology Corp
< Previous
1
2
Next >
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
April 25, 2022
Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer...
Via
FinancialNewsMedia
Topics
Intellectual Property
BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction
April 25, 2022
Vancouver, BC – April 25, 2022 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has entered into an agreement with the Deaconess Research...
Via
FinancialNewsMedia
Topics
Economy
The Power Play by The Market Herald Releases Interviews With Monarch Mining, Vox, Tocvan Ventures, GeneTether Therapeutics, Peloton Minerals, SWMBRD Sports, and BioVaxys Technology Corp.
March 30, 2022
VANCOUVER, BC / ACCESSWIRE / March 30, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Monarch Mining, Vox, Tocvan Ventures, GeneTether Therapeutics, Peloton...
From
The Market Herald
Via
AccessWire
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
March 24, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2022 – USA News Group – Whenever a new COVID-19 variant emergences, health authorities have had limited options to fight...
Via
FinancialNewsMedia
Biotech Sector’s Response to Omicron Panic Should be Swift and Effective
December 07, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC – December 7, 2021 – USA News Group – Despite a level of panic that JP Morgan has already downplayed in its 2022 forecasts, the...
Via
FinancialNewsMedia
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
December 07, 2021
Palm Beach, FL – December 7, 2021 – FinancialNewsMedia.com News Commentary There are many unknowns surrounding the new omicron Covid variant; there are early signs it’s more transmissible, but it’s not...
Via
FinancialNewsMedia
Covid-19 Test Shortage Emphasized by New $70M Plan to Speed Up Authorizations
November 09, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 9, 2021 – USA News Group – New at-home Covid tests are on the way, according to the Biden administration, which announced...
Via
FinancialNewsMedia
Global COVID-19 Therapeutics Market Size Now Expected To Exceed $25 Billion In 2030
November 09, 2021
Palm Beach, FL – November 9, 2021 – FinancialNewsMedia.com News Commentary – The increasing outbreak of covid-19 is increasing the demand for coronavirus vaccines or therapies, which will result in the...
Via
FinancialNewsMedia
Topics
Death
BioVaxys announces that CoviDTH Demonstrates Safety and Tolerability in Broad Ranging In Vivo Clinical Pathology, Immunology, and Histopathology Evaluation, Supporting Planned Clinical Development of CoviDTH
November 09, 2021
VANCOUVER, BC – November 9, 2021 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”), announced today that results from its in vivo animal research study support...
Via
FinancialNewsMedia
Faster, Cheaper, More Reliable COVID-19 Tests Needed for the Unprecedented Demand Ahead
October 20, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC –October 20, 2021 – USA News Group – It may have its beginning for the UK travel industry, but there are signs of the end of using...
Via
FinancialNewsMedia
Scientific Reports Revealing Early Promise for Universal Coronavirus Vaccine
October 20, 2021
Palm Beach, FL – October 20, 2021 – FinancialNewsMedia.com News Commentary – Recently, scientific reports have shown that a universal coronavirus vaccine that protects against COVID-19 causing...
Via
FinancialNewsMedia
BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine
October 20, 2021
Vancouver, BC – October 20, 2021 – BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) (FRA:5LB) (“BioVaxys” or “Company”) announced today that it has filed with the United States Patent & Trademark...
Via
FinancialNewsMedia
Topics
Intellectual Property
New Covid-19 Vaccines Continue to Be Developed by Biotech Firms Seeking to Improve the Jab
October 06, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC –October 6, 2021 – USA News Group – As vaccine passport programs continue to roll out in new markets across the globe, especially in...
Via
FinancialNewsMedia
Big Changes Coming to Covid Testing in Response to Rising Demand Under Latest Mandates
September 28, 2021
Via
FinancialNewsMedia
Why Some Experts Say for an Effective COVID Vaccine, Look Beyond Antibodies to T-Cells
September 28, 2021
Via
FinancialNewsMedia
BIOVAXYS BEGINS TOXICITY STUDY AHEAD OF COVIDTH IND SUBMISSION
September 28, 2021
Via
FinancialNewsMedia
Rare Adverse Effects Continue to Fuel Covid-19 Vaccine Hesitancy, Despite Safety Breakthroughs
September 23, 2021
Via
FinancialNewsMedia
BIOVAXYS PREPARES FOR GROUND-BREAKING STUDY ON REDUCED ACE2 BINDING CAPABILITIES OF HAPTEN-MODIFIED SARS-COV-2 PROTEINS
September 23, 2021
Via
FinancialNewsMedia
Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots
September 17, 2021
Via
FinancialNewsMedia
As the Virus Continues, the Global Covid-19 Vaccine Market Expected to Reach $25 Billion By 2024
September 23, 2021
Via
FinancialNewsMedia
Why New Covid-19 Test Supplies Will Be Needed Soon in Wake of US President’s New OSHA Mandates
September 14, 2021
Via
FinancialNewsMedia
FURTHER STUDY IN HUMANS SHOWS THAT THE DTH RESPONSE, THE BASIS FOR CoviDTH, IS HIGHLY DURABLE AND PERSISTS FOR AT LEAST ONE YEAR AFTER COVID-19 EXPOSURE OR VACCINE ADMINISTRATION
September 08, 2021
Via
FinancialNewsMedia
Why Pharmaceutical Companies in Ovarian Cancer Drugs Market are Betting Big on R&D
September 17, 2021
Via
FinancialNewsMedia
Topics
Death
Covid-19 Tests Innovations Drawing New Interest from FDA and Consortiums
July 22, 2021
Via
FinancialNewsMedia
Biotechs Zero in on Growing Ovarian Cancer Market as Pivotal Trials Advance Through Regulatory Agencies
May 03, 2021
Via
FinancialNewsMedia
Topics
Death
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients
September 14, 2021
Via
FinancialNewsMedia
Delta Variant Infections of COVID Rising Quickly & Now Responsible for 83% of All U.S. Cases
July 22, 2021
Via
FinancialNewsMedia
Why ‘Killer’ T Cells Could Boost COVID Immunity In Face Of New Variants
May 20, 2021
Via
FinancialNewsMedia
< Previous
1
2
Next >
